COVID 19 impact and predictive factors for mortality in cancer patients

Background: SARS-CoV-2 is a novel coronavirus that has been responsible for the largest pandemic in the last century: COVID-19 This disease has widely affected Spain with a high lethality in ancient patients (pts) and with comorbidities Oncological pts were not an exception Methods: We evaluated the association between COVID-19 mortality and clinical/laboratory/radiological parameters in cancer pts from March to April 2020 at our institution Past medical history and COVID-19-related parameters (symptoms, laboratory/x-ray findings and treatments) were retrospectively collected Univariate analysis (UA) has been done using Fisher exact and U-Mann-Withney test for qualitative and quantitative variables, respectively Multivariant analysis (MA) has been done using logistic regression Results: Forty three hospitalized pts were diagnosed with COVID-19;30 pts (69 8%) were symptomatic on admission and 13 pts (30 2%) were hospital-acquired cases Median age was 68 8 ± 7 8 years Most part of the pts had gastrointestinal (GI) (13;30 2%), thoracic (Tx) (12;27 9%) and breast (6;14%) cancer A higher prevalence of Tx tumours compared to our new pts prevalence is observed (9%) Fever was the most common symptom (27;62 8%) and bilateral pneumonia was observed in 24 pts (55 8%) SARS-Co-V-2 PCR was positive in 34 pts (79 1%) Hydroxychloroquine was administered in 35 pts (81 4%), steroids and antiretrovirals in 19 pts (44 1%) and tocilizumab in 12 pts (27 9%) Mortality rate due to COVID-19 was 30 23% (13 pts) and 8 pts could resume oncological treatment Hypertension (HTA) and previous daily steroids given during last month before admission;as well as performance status, fever, Curb-65, SOFA score and D-Dimer (DD) at admission were associated with COVID-19 mortality in UA Similarly, high flow oxygen requirements during hospitalization and DD at 72 hours are predictors of mortality HTA [OR: 8 3 (1-5-70 1)], steroids [OR: 10 7 (1 3 – 143 8)] and fever [OR: 0 09 (0 01 – 0 55)]were also associated in MA Conclusions: COVID-19 showed a relative higher incidence in pts with Tx and GI tumours Some clinical and laboratory parameters were found to be predictive factors for mortality as previously reported in non-cancer pts Further investigations with larger number of pts are needed Legal entity responsible for the study: HM Hospitales Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest